Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature

RATIONALE: With the advancement of targeted therapies, epidermal growth factor receptor tyrosine kinase inhibitors have become the preferred initial treatment for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Osimertinib, a third-generation epider...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Qiang, Feng, Weiqiang, Hu, Sheng, Ye, Jiayue, Wang, Silin, Su, Lang, Zhang, Yang, Zhang, Deyuan, Zhang, Wenxiong, Xu, Jianjun, Wei, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470715/
https://www.ncbi.nlm.nih.gov/pubmed/37653755
http://dx.doi.org/10.1097/MD.0000000000034545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470715/
https://www.ncbi.nlm.nih.gov/pubmed/37653755
http://dx.doi.org/10.1097/MD.0000000000034545

Ejemplares similares